FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025766796> ?p ?o ?g. }

• W2025766796 endingPage "185" @default.
• W2025766796 startingPage "180" @default.
• W2025766796 abstract "Purpose of review Trials treating human rheumatic diseases with biologic agents and drugs that selectively affect B cells will be reviewed. Rituximab, an anti-CD20 monoclonal mouse/human antibody, will be the primary focus of the review because it has been widely used in several autoimmune and rheumatic conditions, but the limited studies on other reagents such as anti-BlyS, anti-CD154, and B cell tolerogens will also be covered. Recent findings The single most important recent development was the completion of a randomized, double-blind, placebo-controlled trial of rituximab in methotrexate-resistant rheumatoid arthritis. In this trial, B cell depletion with rituximab led to a sustained clinical response with an impressive improvement in America College of Rheumatology 50% response (ACR 50) at both 24 and 48 weeks. Additional open studies of rituximab showing clinical benefit in systemic lupus erythematosus, cryoglobulinemia, antineutrophil cytoplasmic antibodies+ vasculitis, and dermatomyositis are noteworthy but must be interpreted with caution until randomized control trials are available. Two well-designed studies of anti-CD154 antibodies in systemic lupus erythematosus were reported. Unfortunately, one was halted because of unexpected vascular complications, and the other failed to show any beneficial clinical effect. A phase I study using anti-BlyS in SLE demonstrated a selective effect on B cells and no overt toxicity, but in this very short-term study no effect on serology or clinical activity was seen. Two B cell tolerogens have been used in human trials. The first tolerogen, directed at anti-dsDNA responses in SLE, did significantly decrease titers of high-affinity anti-dsDNA antibodies but had no clinically beneficial effect overall. A phase I trial of a tolerogen directed at anti-β2-glycoprotein I antibodies demonstrated a decrease in antibody titers after a single injection. Summary Several therapeutic agents targeting B cells have now been tested or are being tested in human trials. The success of rituximab in a well-controlled trial confirms previous preliminary reports indicating that B cell depletion can treat established autoimmune disease." @default.
• W2025766796 created "2016-06-24" @default.
• W2025766796 creator A5002780483 @default.
• W2025766796 creator A5031145721 @default.
• W2025766796 creator A5074507227 @default.
• W2025766796 date "2004-05-01" @default.
• W2025766796 modified "2023-10-13" @default.
• W2025766796 title "B cells as therapeutic targets for rheumatic diseases" @default.
• W2025766796 cites W1574744856 @default.
• W2025766796 cites W1603245933 @default.
• W2025766796 cites W1977206110 @default.
• W2025766796 cites W1979336667 @default.
• W2025766796 cites W1981661724 @default.
• W2025766796 cites W1983339176 @default.
• W2025766796 cites W1988862282 @default.
• W2025766796 cites W2000404840 @default.
• W2025766796 cites W2009154052 @default.
• W2025766796 cites W2011261778 @default.
• W2025766796 cites W2017709470 @default.
• W2025766796 cites W2017925927 @default.
• W2025766796 cites W2021257197 @default.
• W2025766796 cites W2021830136 @default.
• W2025766796 cites W2028453745 @default.
• W2025766796 cites W2029957805 @default.
• W2025766796 cites W2046059252 @default.
• W2025766796 cites W2046900942 @default.
• W2025766796 cites W2053113431 @default.
• W2025766796 cites W2054596819 @default.
• W2025766796 cites W2057338076 @default.
• W2025766796 cites W2069282346 @default.
• W2025766796 cites W2075335899 @default.
• W2025766796 cites W2077409993 @default.
• W2025766796 cites W2078610240 @default.
• W2025766796 cites W2087810525 @default.
• W2025766796 cites W2107002794 @default.
• W2025766796 cites W2117486036 @default.
• W2025766796 cites W2132562982 @default.
• W2025766796 cites W2134451223 @default.
• W2025766796 cites W2144479507 @default.
• W2025766796 cites W2151988044 @default.
• W2025766796 cites W2164006259 @default.
• W2025766796 cites W2325989577 @default.
• W2025766796 cites W2415998525 @default.
• W2025766796 cites W4230977854 @default.
• W2025766796 cites W4231322642 @default.
• W2025766796 cites W4233885503 @default.
• W2025766796 cites W4245787426 @default.
• W2025766796 cites W4249342726 @default.
• W2025766796 cites W60759546 @default.
• W2025766796 doi "https://doi.org/10.1097/00002281-200405000-00003" @default.
• W2025766796 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15103242" @default.
• W2025766796 hasPublicationYear "2004" @default.
• W2025766796 type Work @default.
• W2025766796 sameAs 2025766796 @default.
• W2025766796 citedByCount "108" @default.
• W2025766796 countsByYear W20257667962012 @default.
• W2025766796 countsByYear W20257667962013 @default.
• W2025766796 countsByYear W20257667962014 @default.
• W2025766796 countsByYear W20257667962016 @default.
• W2025766796 countsByYear W20257667962017 @default.
• W2025766796 countsByYear W20257667962018 @default.
• W2025766796 countsByYear W20257667962019 @default.
• W2025766796 countsByYear W20257667962021 @default.
• W2025766796 countsByYear W20257667962022 @default.
• W2025766796 countsByYear W20257667962023 @default.
• W2025766796 crossrefType "journal-article" @default.
• W2025766796 hasAuthorship W2025766796A5002780483 @default.
• W2025766796 hasAuthorship W2025766796A5031145721 @default.
• W2025766796 hasAuthorship W2025766796A5074507227 @default.
• W2025766796 hasConcept C126322002 @default.
• W2025766796 hasConcept C159654299 @default.
• W2025766796 hasConcept C170286685 @default.
• W2025766796 hasConcept C198451711 @default.
• W2025766796 hasConcept C203014093 @default.
• W2025766796 hasConcept C2776015282 @default.
• W2025766796 hasConcept C2777575956 @default.
• W2025766796 hasConcept C2778453870 @default.
• W2025766796 hasConcept C2778751314 @default.
• W2025766796 hasConcept C2779134260 @default.
• W2025766796 hasConcept C2780653079 @default.
• W2025766796 hasConcept C2781205201 @default.
• W2025766796 hasConcept C535046627 @default.
• W2025766796 hasConcept C71924100 @default.
• W2025766796 hasConceptScore W2025766796C126322002 @default.
• W2025766796 hasConceptScore W2025766796C159654299 @default.
• W2025766796 hasConceptScore W2025766796C170286685 @default.
• W2025766796 hasConceptScore W2025766796C198451711 @default.
• W2025766796 hasConceptScore W2025766796C203014093 @default.
• W2025766796 hasConceptScore W2025766796C2776015282 @default.
• W2025766796 hasConceptScore W2025766796C2777575956 @default.
• W2025766796 hasConceptScore W2025766796C2778453870 @default.
• W2025766796 hasConceptScore W2025766796C2778751314 @default.
• W2025766796 hasConceptScore W2025766796C2779134260 @default.
• W2025766796 hasConceptScore W2025766796C2780653079 @default.
• W2025766796 hasConceptScore W2025766796C2781205201 @default.
• W2025766796 hasConceptScore W2025766796C535046627 @default.
• W2025766796 hasConceptScore W2025766796C71924100 @default.
• W2025766796 hasIssue "3" @default.

• next